A fund manager expects huge amounts of investment funds and the fear of missing out to bring new buyers, especially if progress continues on the tariff front and the inflation impact is less than feared.
The company reported diluted net income per share of $0.13 for the three months through the end of March, compared to a loss of $0.28 in the corresponding period of 2024.
Wall Street's rally stretched into a second session Tuesday, fueled by improving investor sentiment after an early-week breakthrough in U.S.-China trade talks, easing inflation data and fresh geopolitical headlines involving major investment pledges from the Middle East.
In the second quarter, the firm expects to announce data from a phase 2 trial of its investigational therapy, Pemvidutide, in treating metabolic dysfunction-associated steatohepatitis (MASH).
Tariff news flow, first-tier economic data, and a few earnings reports could decide the day's trading direction, although the momentum is decisively in favor of further gains.
The company also reiterated its full-year total revenue guidance of $250 million to $260 million and net product sales guidance of $240 million to $250 million.
U.S. Trade Representative Jamieson Greer stated that the speed with which the U.S. and China could reach an agreement showed that perhaps the differences were not as large as initially thought.
Wall Street traded slightly lower by midday Friday, as investors adopted a wait-and-see stance ahead of a potential trade breakthrough, with high-stakes negotiations between U.S. officials—led by Treasury Secretary Scott Bessent—and Chinese authorities set to unfold over the weekend.
CEO Shankar Musunuri said that the company is “on track” to meet its goal of submitting applications to the FDA requesting approval for the distribution of three of its products in the next three years.
The combination of Avutometinib capsules and Defactinib tablets, under the brand name Avmapki Fakzynja Co-pack, can now be used to treat patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior treatment.
The company raised its full-year revenue guidance to between $975 million and $1.025 billion, up from its previous guidance of between $300 million and $350 million.
U.S. stocks rallied Thursday after the Trump administration signed its first major trade agreement with the United Kingdom, igniting optimism about further global deals — especially with China — and lifting investor appetite for riskier assets.
The company reported net revenue of $39.1 million for the first quarter from the sales of DefenCath, above an analyst estimate of $36, as per Finchat data.
U.S. stocks traded mixed at midday Wednesday, as investors remained cautious ahead of the Federal Reserve’s upcoming policy decision, with Chair Jerome Powell set to speak at 2:30 p.m. ET.
Wall Street edged lower by midday Tuesday as uncertainty surrounding trade policies lingered, with investors adopting a cautious approach ahead of Wednesday’s Federal Reserve meeting.
According to Morgan Stanley's Matt Wilson, the 5,750-5,800 area — the convergence of the 200-day and 100-day moving averages — is the most critical technical test for the S&P 500 Index.
Wall Street kicked off the week with a cautious tone, as major stock indices hovered near the flatline by midday in New York. Investors digested fresh signs of inflationary pressure in the services sector, raising doubts about near-term rate cuts and weighing on risk appetite.
BioCryst now expects global net Orladeyo revenue to be between $580 million and $600 million for the full year, up from its previous guidance of between $535 million and $550 million.
